Related Experiment Video
Updated: May 2, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.0K
Recombinant activated factor VII in cardiac surgery: single-center experience
Sarvesh Pal Singh1, Sandeep Chauhan, Minati Choudhury
1Department of Cardiac Anesthesia, All India Institute of Medical Sciences, New Delhi, India.
Asian Cardiovascular & Thoracic Annals
|March 4, 2014
Summary
Recombinant activated factor VII (rFVIIa) is effective for postoperative hemorrhage, with lower doses needed in adults than children. Prophylactic rFVIIa use reduces complications and ICU stay but shows no survival benefit.
Area of Science:
- Cardiovascular Surgery
- Hemorrhage Control
- Pharmacology
Background:
- Off-label use of recombinant activated factor VII (rFVIIa) persists for refractory postoperative hemorrhage despite FDA warnings.
- rFVIIa effectively reduces transfusion needs but raises safety concerns.
Purpose of the Study:
- Compare rFVIIa dosing and efficacy in pediatric vs. adult patients.
- Evaluate rFVIIa use in the operating room vs. intensive care unit settings.
Main Methods:
- Retrospective review of 69 cardiovascular surgery patients (33 children, 36 adults) who received rFVIIa.
- Analysis of rFVIIa dose, mediastinal drainage, transfusion requirements, thrombosis incidence, and 28-day mortality.
Main Results:
- Comparable rFVIIa efficacy in adults and children, with lower doses in adults.
- Prophylactic rFVIIa use decreased mediastinal exploration and ICU stay duration.
- A 4.3% incidence of thrombotic complications was observed.
Conclusions:
- Efficacious rFVIIa dose is significantly lower in adults compared to children.
- Prophylactic rFVIIa reduces required dose, mediastinal exploration, and ICU stay.
- No survival benefit was observed with rFVIIa use.
